Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038454 (
stroke
)
147,016
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Among hypertension-associated cardiovascular diseases,
stroke
represents one of the most common disorders. In fact, it significantly affects mortality and morbidity rates of all industrialized countries. Only recently,
stroke
has been considered as a complex trait and not as a mere consequence of hypertension. Indeed, it appears to be the result of an interaction among several genetic and environmental factors. The identification of the genetic determinants of
stroke
is a difficult task in humans, due to the genetic heterogeneity of human populations and the confounding presence of other risk factors. Thus, an experimental approach, through the use of a highly inbred animal model for
stroke
, offers a valuable alternative and additional support for a genetic dissection of cerebrovascular disease. In fact, the genetic analysis of
stroke
in the animal model of the
stroke
-prone spontaneously hypertensive rat provided clear evidence that
stroke
is a genetically determined complex trait, and that factors such as blood pressure and diet only play a permissive role. Finally, by using the experimental approach, we established that the gene encoding
atrial natriuretic peptide
, significantly linked to cerebrovascular disease in rats, is a genetic determinant of
stroke
in humans. The identification of the genetic basis of
stroke
represents an important step towards the institution of targeted preventive and therapeutic approaches to reduce the risks of cerebrovascular accidents. This article reviews the background, the experimental approach and the outcome of a strategy based on the use of the
stroke
-prone spontaneously hypertensive rat model, which aims at identifying the genetic basis of
stroke
.
...
PMID:Genetic basis of cerebrovascular accidents associated with hypertension. 1038 47
The purpose of the present experiments was to define the role of C-type natriuretic peptide (CNP) in the regulation of atrial secretion of
atrial natriuretic peptide
(
ANP
) and atrial
stroke
volume. Experiments were performed in perfused beating and nonbeating quiescent atria, single atrial myocytes, and atrial membranes. CNP suppressed in a dose-related fashion the increase in atrial
stroke
volume and
ANP
secretion induced by atrial pacing. CNP caused a right shift in the positive relationships between changes in the secretion of
ANP
and atrial
stroke
volume or translocation of the extracellular fluid (ECF), which indicates the suppression of atrial myocytic release of
ANP
into the paracellular space. The effects of CNP on the secretion and contraction were mimicked by 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP). CNP increased cGMP production in the perfused atria, and the effects of CNP on the secretion of
ANP
and atrial dynamics were accentuated by pretreatment with an inhibitor of cGMP phosphodiesterase, zaprinast. An inhibitor of the biological natriuretic peptide receptor (NPR), HS-142-1, attenuated the effects of CNP. The suppression of
ANP
secretion by CNP and 8-BrcGMP was abolished by a depletion of extracellular Ca(2+) in nonbeating atria. Natriuretic peptides increased cGMP production in atrial membranes with a rank order of potency of CNP > BNP >
ANP
, and the effect was inhibited by HS-142-1. CNP and 8-BrcGMP increased intracellular Ca(2+) concentration transients in single atrial myocytes, and mRNAs for CNP and NPR-B were expressed in the rabbit atrium. From these results we conclude that atrial
ANP
release and
stroke
volume are controlled by CNP via NPR-B-cGMP mediated signaling, which may in turn act via regulation of intracellular Ca(2+).
...
PMID:C-type natriuretic peptide inhibits ANP secretion and atrial dynamics in perfused atria: NPR-B-cGMP signaling. 1064 1
Previous studies have shown that short-term high salt intake unmasks blunted plasma aldosterone suppression in
stroke
-prone spontaneously hypertensive rats (SHRsp). The aim of this study was to evaluate the response of aldosterone biosynthesis and production to a sustained exposure to the
stroke
-permissive Japanese-style diet (JD) in young
stroke
-prone and
stroke
-resistant SHRs. For this purpose, 6-week old male rats from both strains were divided into 2 dietary groups and received regular diet (SHR = 37, SHRsp = 32) or the JD and 1% saline to drink (SHR = 34, SHRsp = 30) for 4 weeks. All measurements were carried out at the end of the dietary periods. After JD, plasma aldosterone levels were significantly decreased in SHR (from 357.8 +/- 57 to 163.3 +/- 31.5 pg/ml, p < 0.05) but markedly increased in SHRsp (from 442 +/- 56.5 to 739 +/- 125.7 pg/ml, p < 0.05). Consistently, the adrenal aldosterone synthase expression was reduced by JD in SHR (p < 0.05), whereas it was even slightly raised by JD in SHRsp so that, at the end of JD, aldosterone synthase mRNA was 5-fold higher in SHRsp than in SHR. Urinary sodium excretion (mEq/24h) achieved lower levels in SHRsp, so that fractional excretion of sodium was 80.2 +/- 9% in SHR and 40.3 +/- 8% in SHRsp (p < 0.05) in balance studies performed at the end of JD. These different responses of mineralocorticoid biosynthesis and urinary sodium excretion to JD were not accounted for by different adaptations of the renin-angiotensin and
atrial natriuretic peptide
systems, of serum potassium levels, or of adrenal 11beta-hydroxylase expression in the two strains. Systolic blood pressure was comparable in both strains throughout the experiment. These results demonstrate enhanced aldosterone biosynthesis, associated with reduced urinary excretion of sodium in response to JD in SHRsp before the onset of
stroke
. This abnormality may play a role in the higher susceptibility to
stroke
of this model.
...
PMID:Defective suppression of the aldosterone biosynthesis during stroke permissive diet in the stroke-prone phenotype of the spontaneously hypertensive rat. 1082 99
Stroke
(brain attack) is currently the third leading cause of death in Western societies. Recent advances in molecular genetics have finally demonstrated what has long been suggested by the clinical observation, that is,
stroke
is not only the complication of major pathologic conditions such as atherosclerosis, hypertension, or cardiac diseases, but rather it represents a complex trait itself. Thus, the pathogenesis of
stroke
is often the result of the combined effects of genes exerting a direct contributory role and of their interactions with several environmental determinants. A genetic dissection of
stroke
has been attempted in suitable animal models and in humans. With this approach, the genetic defects underlying monogenic disorders associated with
stroke
were identified. Moreover, important findings have recently highlighted the contribution of genes encoding cardiovascular hormones, such as the
atrial natriuretic peptide
, for the pathogenesis of multifactorial, polygenic forms of
stroke
. A more thorough understanding of the fine mechanisms, dependent from mutations within
stroke
susceptibility genes and underlying the disease pathogenesis, may help to introduce new specific tools to achieve better prevention and treatment of
stroke
.
...
PMID:Etiology and pathophysiology of stroke as a complex trait. 1104 Nov 70
Atrial secretion of
atrial natriuretic peptide
(
ANP
) has been shown to be regulated by atrial workload. Although modulating factors for the secretion of
ANP
have been reported, the role for intracellular Ca(2+) on the secretion of
ANP
has been controversial. The purpose of the present study was to define roles for L- and T-type Ca(2+) channels in the regulation of
ANP
secretion in perfused beating rabbit atria. BAY K 8644 (BAY K) increased atrial
stroke
volume and pulse pressure. BAY K suppressed
ANP
secretion and
ANP
concentration in terms of extracellular fluid (ECF) translocation concomitantly with an increase in atrial dynamics. BAY K shifted the relationship between
ANP
secretion and ECF translocation downward and rightward. These results indicate that BAY K inhibits myocytic release of
ANP
. In the continuous presence of BAY K, diltiazem reversed the effects of BAY K. Diltiazem alone increased
ANP
secretion and
ANP
concentration along with a decrease in atrial dynamics. Diltiazem shifted relationships between
ANP
secretion and atrial
stroke
volume or ECF translocation leftward. The T-type Ca(2+) channel inhibitor mibefradil decreased atrial dynamics. Mibefradil inhibited
ANP
secretion and
ANP
concentration in contrast with the L-type Ca(2+) channel inhibitor. These results suggest that activation of L- and T-type Ca(2+) channels elicits opposite effects on atrial myocytic release of
ANP
.
...
PMID:Distinct roles for L- and T-type Ca(2+) channels in regulation of atrial ANP release. 1108 44
Association between exogenous
atrial natriuretic peptide
(
ANP
) and hemodynamic changes was ascertained in 3 dogs with overt congestive heart failure (CHF(+)) and 3 dogs without congestive heart failure (CHF(-)) caused by experimental mitral regurgitation (MR). The hemodynamic measurements were recorded in all dogs during and after 1 hr infusion of
ANP
at the rate of 0.1 (low dose), 0.5 (medium dose) and 1.0 (high dose) microg/kg/min, respectively. Heart rate, mean arterial pressure, pulmonary capillary wedge pressure (PCWP) and systemic vascular resistance decreased significantly during and after
ANP
infusion even with low dose in the CHF(+).
Stroke
volume,
stroke
volume index and cardiac output in the CHF(+) during and after
ANP
infusion showed an increasing trend as compared with the CHF(-). Double product, an indicator of myocardial oxygen consumption, significantly decreased during and after
ANP
administration at all doses in the CHF(+). These findings indicate that even at low dose, exogenous
ANP
improves cardiac performance and reduces myocardial oxygen consumption in the CHF(+), and suggest that
ANP
has beneficial effects in the treatment of dogs with overt congestive heart failure resulting from MR.
...
PMID:Association between exogenous atrial natriuretic peptide and hemodynamics in dogs with congestive heart failure produced by experimental mitral regurgitation. 1130 23
A quantitative trait locus on chromosome 5 in the rat is linked to sensitivity to brain ischemia in the
stroke
-prone spontaneously hypertensive rat (SHRSP). The genes encoding
atrial natriuretic peptide
(
ANP
) and brain natriuretic peptide (BNP) that map to this location have been excluded as candidate genes. We examined dishevelled-1 (DVL-1) as a further candidate gene. DVL-1 had not yet been identified in the rat, but Anp, Bnp, and DVL-1 map to the homologous regions of the rat chromosome 5 quantitative trait locus in both mice and man. Furthermore, DVL-1 is involved in the Notch signalling system, which plays a role in the disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, the symptoms of, which include ischaemic
stroke
. We show with radiation hybrid mapping that rat DVL-1 indeed maps to chromosome 5, where it is positioned immediately next to microsatellite marker D5Rat49. We sequenced the complete coding sequence and a large part of the intronic genomic sequence for the SHRSP strain and its reference Wistar-Kyoto strain. The DVL-1 sequence in the two strains was identical. Our results essentially exclude the DVL-1 gene as the cause for sensitivity to cerebral ischaemic insult in this rat model of
stroke
.
...
PMID:Mapping and sequencing rat dishevelled-1: a candidate gene for cerebral ischaemic insult in a rat model of stroke. 1135 32
Omapatrilat, a novel vasopeptidase inhibitor, is a highly potent and selective inhibitor of neutral endopeptidase and angiotensin-converting enzyme; its therapeutic potential is being investigated for treatment of hypertension and heart failure. In the present study, the safety, tolerability, and hemodynamic effects of single oral doses of omapatrilat (1 to 50 mg) are compared with placebo in patients with heart failure. Patients with heart failure (New York Heart Association functional class II to IV) and a resting left ventricular ejection fraction < or = 40% were enrolled in a double-blind, placebo-controlled, sequential-panel study of single doses of omapatrilat of 1, 2.5, 5, 10, 25, or 50 mg, followed by hemodynamic assessment for 24 hours. At 4 to 6 hours after dosing, the 25- and 50-mg doses of omapatrilat, compared with placebo, reduced mean pulmonary capillary wedge pressure by approximately 6 mm Hg from 20 and 23 mm Hg at baseline to 14 and 16 mm Hg. The 50-mg omapatrilat dose maintained this effect compared with placebo with an approximately 2.5-mm Hg reduction in mean pulmonary capillary wedge pressure at 24 hours. Omapatrilat improved additional hemodynamic parameters, including cardiac index, systemic vascular resistance,
stroke
volume index, and mean arterial pressure. Additionally, by 2 hours after dosing with omapatrilat 25 and 50 mg, a trend in peak increases from baseline in plasma
atrial natriuretic peptide
(twofold) and cyclic guanosine monophosphate (nearly twofold) was observed. Moreover, omapatrilat was well tolerated. Thus, omapatrilat administered orally to patients with heart failure was safe and well tolerated and resulted in improved hemodynamic performance.
...
PMID:Effects of omapatrilat on hemodynamics and safety in patients with heart failure. 1156 90
The
atrial natriuretic peptide
(
ANP
) gene may underlie
stroke
susceptibility and sensitivity to cerebral ischemia in an animal model of
stroke
. The authors investigate its role in humans by genotyping a polymorphism (G664A) in 436 patients with ischemic cerebrovascular disease and 295 community control subjects. The frequency of this variant was similar in both groups and across the different
stroke
subtypes. The
ANP
gene G664A polymorphism is therefore unlikely to be an important risk factor for ischemic
stroke
in this population.
...
PMID:Atrial natriuretic peptide gene G664A polymorphism and the risk of ischemic cerebrovascular disease. 1170 24
The hypothesis was tested that acute water immersion to the neck (WI) compared with 6 degrees head-down tilt (HDT) induces a more pronounced distension of the heart and lower plasma levels of vasoconstrictor hormones. Ten healthy males underwent 30 min of HDT, WI, and a seated control (randomized). During WI, left atrial diameter and
stroke
volume increased to the same extent as during HDT. Cardiac output increased by 1 l/min more during WI than during HDT. (P < 0.05). Plasma
atrial natriuretic peptide
increased during WI (P < 0.05) but not during HDT, whereas plasma norepinephrine, vasopressin, and renin activity were suppressed similarly. Mean arterial pressure decreased by 9 mmHg (P < 0.05) during HDT and was unchanged during WI, and heart rate decreased more during HDT (P < 0.05). Arterial pulse pressure increased considerably more during HDT than during WI. In conclusion, the hypothesis was not confirmed because the cardiac atria were similarly distended by acute HDT and WI and the release of vasoconstrictor hormones were suppressed to the same extent.
...
PMID:Comparison of acute cardiovascular responses to water immersion and head-down tilt in humans. 1174 69
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>